Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11314007rdf:typepubmed:Citationlld:pubmed
pubmed-article:11314007lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:11314007lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11314007lifeskim:mentionsumls-concept:C0005682lld:lifeskim
pubmed-article:11314007lifeskim:mentionsumls-concept:C0006141lld:lifeskim
pubmed-article:11314007lifeskim:mentionsumls-concept:C0005558lld:lifeskim
pubmed-article:11314007lifeskim:mentionsumls-concept:C1148673lld:lifeskim
pubmed-article:11314007lifeskim:mentionsumls-concept:C1823878lld:lifeskim
pubmed-article:11314007lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:11314007lifeskim:mentionsumls-concept:C2266866lld:lifeskim
pubmed-article:11314007lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:11314007pubmed:issue6lld:pubmed
pubmed-article:11314007pubmed:dateCreated2001-4-23lld:pubmed
pubmed-article:11314007pubmed:abstractTextThe Ku70/80 heterodimer is the regulatory subunit of the DNA-dependent protein kinase (DNA-PK) and its DNA-binding activity mediates DNA double-strand breaks repair. Although Ku80 was recently proposed as a caretaker gene involved in the control of genome integrity, no data are available on Ku70/80 DNA-binding activity in human tumors. Heterodimer DNA-binding activity and protein expression were assayed by electrophoretic-mobility-shift-assay (EMSA) and Western blot analysis, in nuclear and cytoplasmic extracts from eight breast, seven bladder primary tumors and three metastatic nodes from breast cancers. Corresponding normal tissues of the same patients were used as controls. Ten out of 15 tumors showed nuclear Ku-binding activity 3-10 times higher than in the normal tissues, irrespective of bladder or breast origin. Conversely, in 5/15 primary tumors and in all the metastatic nodes analysed, nuclear Ku-activity was 1.5-4.5-fold lower than in the corresponding normal tissues. Cytoplasmic heterodimer activity significantly differed between tumor and normal tissues, displaying a 2-10-fold increase in neoplastic tissues. Three different patterns combining both Ku expression and activity with tumor characteristics were identified. In low aggressive breast tumors p70/p80 proteins were expressed in tumor but not in normal tissues. The heterodimer binding-activity matched the protein levels. In non-invasive bladder carcinomas no significant differences in protein expression between tumor and the corresponding normal tissues were found, however heterodimer binding-activity was increased in tumor samples. In breast and bladder tumors, at the advanced stage and in node metastases, the binding activity was strongly reduced in tumor biopsies, however no differences were demonstrated between normal and tumor protein levels. Our results suggest a different modulation of Ku70/80 DNA-binding activity in human neoplastic tissues, possibly related to tumor progression. Findings provide further data on tissue-specific protein expression and post-translational regulation of heterodimer activity.lld:pubmed
pubmed-article:11314007pubmed:languageenglld:pubmed
pubmed-article:11314007pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11314007pubmed:citationSubsetIMlld:pubmed
pubmed-article:11314007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11314007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11314007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11314007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11314007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11314007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11314007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11314007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11314007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11314007pubmed:statusMEDLINElld:pubmed
pubmed-article:11314007pubmed:monthFeblld:pubmed
pubmed-article:11314007pubmed:issn0950-9232lld:pubmed
pubmed-article:11314007pubmed:authorpubmed-author:GallucciMMlld:pubmed
pubmed-article:11314007pubmed:authorpubmed-author:RabittiCClld:pubmed
pubmed-article:11314007pubmed:authorpubmed-author:FazioV MVMlld:pubmed
pubmed-article:11314007pubmed:authorpubmed-author:MazzarelloVVlld:pubmed
pubmed-article:11314007pubmed:authorpubmed-author:PucciSSlld:pubmed
pubmed-article:11314007pubmed:authorpubmed-author:GiaiMMlld:pubmed
pubmed-article:11314007pubmed:authorpubmed-author:AlcineEElld:pubmed
pubmed-article:11314007pubmed:authorpubmed-author:FlammiaGGlld:pubmed
pubmed-article:11314007pubmed:authorpubmed-author:AltomareVVlld:pubmed
pubmed-article:11314007pubmed:issnTypePrintlld:pubmed
pubmed-article:11314007pubmed:day8lld:pubmed
pubmed-article:11314007pubmed:volume20lld:pubmed
pubmed-article:11314007pubmed:ownerNLMlld:pubmed
pubmed-article:11314007pubmed:authorsCompleteYlld:pubmed
pubmed-article:11314007pubmed:pagination739-47lld:pubmed
pubmed-article:11314007pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:meshHeadingpubmed-meshheading:11314007...lld:pubmed
pubmed-article:11314007pubmed:year2001lld:pubmed
pubmed-article:11314007pubmed:articleTitleTumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies.lld:pubmed
pubmed-article:11314007pubmed:affiliationInstitute of Experimental Medicine, CNR, Via Fosso del Cavaliere 100, 00133 Rome, Italy.lld:pubmed
pubmed-article:11314007pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11314007pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:2547entrezgene:pubmedpubmed-article:11314007lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11314007lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11314007lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11314007lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11314007lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11314007lld:pubmed